Follow
Diamyd Medical AB
Nasdaq First North GM (Sweden)
Diamyd Medical AB is a Sweden based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology. It develops the diabetes vaccine Diamyd, for antigen-specific im Diamyd Medical AB is a Sweden based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology. It develops the diabetes vaccine Diamyd, for antigen-specific immunotherapy based on the licensed GAD-molecule.

Read more

Sector:
HEALTH CARE
>
Biotechnology
Healthcare
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Show archived
Type
Ticker
ISIN
Market
SHARE
DMYD B
SE0005162880
Nasdaq First North GM
Sweden (SE)
Details of share in Diamyd Medical AB with ticker DMYD B
Status
Active
Order book id
Amount of instruments
66 613 573
Par value
Currency
SEK
Segment
First North
Type
Price
Pre-money valuation
Time
Files
Listing
20 May 2013
Direct listing of Diamyd Medical AB on Nasdaq First North GM
Type
Price
Pre-money valuation
Time
Files
Rights issue
2.10 SEK
20.71M SEK
05 Jun - 20 Jun 2013
Share issue in Diamyd Medical AB
Type
Price
Pre-money valuation
Time
Files
Directed issue
7.50 SEK
148.65M SEK
31 Mar 2015
Type
Price
Pre-money valuation
Time
Files
Rights issue
3.00 SEK
66.36M SEK
08 Feb - 22 Feb 2016
Share issue in Diamyd Medical AB
Type
Price
Pre-money valuation
Time
Files
Rights issue
3.50 SEK
128.35M SEK
10 May - 24 May 2017
Share issue in Diamyd Medical AB
Type
Price
Pre-money valuation
Time
Files
Exercise
4.55 SEK
256.32M SEK
01 Nov - 30 Nov 2018
Option exercise terms for DMYD TO 1 B
Type
Ticker
ISIN
Market
SHARE
DMYD B
SE0005162880
Nasdaq First North GM
Sweden (SE)
Details of share in Diamyd Medical AB with ticker DMYD B
Status
Active
Order book id
Amount of instruments
66 613 573
Par value
Currency
SEK
Segment
First North
Type
Price
Pre-money valuation
Time
Files
Listing
20 May 2013
Direct listing of Diamyd Medical AB on Nasdaq First North GM
Type
Price
Pre-money valuation
Time
Files
Rights issue
2.10 SEK
20.71M SEK
05 Jun - 20 Jun 2013
Share issue in Diamyd Medical AB
Type
Price
Pre-money valuation
Time
Files
Directed issue
7.50 SEK
148.65M SEK
31 Mar 2015
Type
Price
Pre-money valuation
Time
Files
Rights issue
3.00 SEK
66.36M SEK
08 Feb - 22 Feb 2016
Share issue in Diamyd Medical AB
Type
Price
Pre-money valuation
Time
Files
Rights issue
3.50 SEK
128.35M SEK
10 May - 24 May 2017
Share issue in Diamyd Medical AB
Type
Ticker
ISIN
Market
OPTION
DMYD TO 1 B
SE0009889199
Nasdaq First North GM
Sweden (SE)
Details of option in Diamyd Medical AB with ticker DMYD TO 1 B
Status
Archived
Order book id
140057
Amount of instruments
25 989 268
Currency
SEK
Segment
First North
Trading period
29 Jun 2017 - 28 Nov 2018
Terms
Two (2) warrants entitles the holder to subscribe for a one (1) new share in the Company for SEK 4.55 per share during the subscription period from November 1, 2018 until November 30, 2018.
Update (19.06.2017): Trading in newly issued shares and warrants in Diamyd Medical starts on June 29, 2017.
Update (01.11.2018): The exercise period of warrants in Diamyd Medical begins today.
Update (26.11.2018): Diamyd Medical reminds of the exercise of warrants.
Type
Price
Pre-money valuation
Time
Files
Exercise
4.55 SEK
256.32M SEK
01 Nov - 30 Nov 2018
Option exercise terms for DMYD TO 1 B
People
Ulf Henrik Hannelius
CEO
Erik Nerpin
Chairman of the board
Anders Essen-Möller
Board member
Maria-Teresa Essen-Möller
Board member
Torbjörn Bäckström
Board member
Mark Atkinson
Board member
Company Details
Sector
HEALTH CARE
Website

Address
Kungsgatan 29
Zip code
111 56
City/district
Stockholm
Country
Sweden (SE)
Registration number
556242-3797
LEI code
5493003NP2HNQDEKB804
First trade date
20 May 2013
Company former names
Diamyd Therapeutics AB
22 Apr 2013
BioSyn Holding AB
15 Jan 1999
Registration date
27 Mar 1984
Short name
Diamyd Medical

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date